Analyst consensus rating
INmune Bio Analyst Rating: Strong Buy
Direct answer
INmune Bio's consensus rating is Strong Buy.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $6.50.
Forecast evidence checked November 16, 2026.
Get free INmune Bio email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.05
- Average price target
- $6.50
- High price target
- $9.00
- Low price target
- $2.50
- Low target gap
- +138.1%
- Target upside
- +519%
- High target gap
- +757.1%
- Target range width
- 619%
- Consensus rating
- Strong Buy
- Analysts
- 3
- Evidence date
- November 16, 2026
- Valid through
- November 23, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for INmune Bio?
INmune Bio has a verified Strong Buy consensus. The same dataset has an average price target of $6.50.
How far are INmune Bio's low and high targets from the recorded price?
The low target implies +138.1%, while the high target implies +757.1%.
How many analysts are included in INmune Bio's consensus?
The verified consensus includes 3 analysts.
How is INmune Bio's target upside or downside calculated?
The average target of $6.50 is divided by the recorded price of $1.05, then one is subtracted to produce +519%. This does not guarantee a future return.
When was INmune Bio's analyst forecast verified?
The data was verified on 2026-11-16. The dataset is valid through 2026-11-23.